Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Other Working Capital Changes (2020 - 2025)

Historic Other Working Capital Changes for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to -$553000.0.

  • Oncology Institute's Other Working Capital Changes fell 30789.47% to -$553000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.3 million, marking a year-over-year decrease of 59032.68%. This contributed to the annual value of -$2.8 million for FY2024, which is 4688.2% up from last year.
  • Per Oncology Institute's latest filing, its Other Working Capital Changes stood at -$553000.0 for Q3 2025, which was down 30789.47% from $359000.0 recorded in Q2 2025.
  • Oncology Institute's 5-year Other Working Capital Changes high stood at $5.7 million for Q2 2021, and its period low was -$3.5 million during Q4 2024.
  • In the last 5 years, Oncology Institute's Other Working Capital Changes had a median value of -$858000.0 in 2022 and averaged -$270842.1.
  • In the last 5 years, Oncology Institute's Other Working Capital Changes soared by 758824.13% in 2021 and then crashed by 2446666.67% in 2022.
  • Oncology Institute's Other Working Capital Changes (Quarter) stood at -$3000.0 in 2021, then plummeted by 24466.67% to -$737000.0 in 2022, then crashed by 91.99% to -$1.4 million in 2023, then crashed by 145.8% to -$3.5 million in 2024, then soared by 84.1% to -$553000.0 in 2025.
  • Its Other Working Capital Changes stands at -$553000.0 for Q3 2025, versus $359000.0 for Q2 2025 and -$1.6 million for Q1 2025.